Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer.
Frantzi M, Gomez Gomez E, Blanca Pedregosa A, Valero Rosa J, Latosinska A, Culig Z, Merseburger AS, Luque RM, Requena Tapia MJ, Mischak H, Carrasco Valiente J. Frantzi M, et al. Among authors: requena tapia mj. Br J Cancer. 2019 Jun;120(12):1120-1128. doi: 10.1038/s41416-019-0472-z. Epub 2019 May 16. Br J Cancer. 2019. PMID: 31092909 Free PMC article.
Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer.
Gómez-Gómez E, Jiménez-Vacas JM, Carrasco-Valiente J, Herrero-Aguayo V, Blanca-Pedregosa AM, León-González AJ, Valero-Rosa J, Fernández-Rueda JL, González-Serrano T, López-Miranda J, Gahete MD, Castaño JP, Requena-Tapia MJ, Luque RM. Gómez-Gómez E, et al. Among authors: requena tapia mj. J Cell Mol Med. 2018 Nov;22(11):5688-5697. doi: 10.1111/jcmm.13845. Epub 2018 Sep 6. J Cell Mol Med. 2018. PMID: 30256519 Free PMC article.
Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.
Gómez-Gómez E, Carrasco-Valiente J, Campos-Hernández JP, Blanca-Pedregosa AM, Jiménez-Vacas JM, Ruiz-García J, Valero-Rosa J, Luque RM, Requena-Tapia MJ. Gómez-Gómez E, et al. Among authors: requena tapia mj. J Cell Mol Med. 2019 Feb;23(2):934-942. doi: 10.1111/jcmm.13994. Epub 2018 Nov 18. J Cell Mol Med. 2019. PMID: 30450757 Free PMC article.
Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer.
Gómez-Gómez E, Jiménez-Vacas JM, Pedraza-Arévalo S, López-López F, Herrero-Aguayo V, Hormaechea-Agulla D, Valero-Rosa J, Ibáñez-Costa A, León-González AJ, Sánchez-Sánchez R, González-Serrano T, Requena-Tapia MJ, Castaño JP, Carrasco-Valiente J, Gahete MD, Luque RM. Gómez-Gómez E, et al. Among authors: requena tapia mj. J Clin Med. 2019 Sep 6;8(9):1400. doi: 10.3390/jcm8091400. J Clin Med. 2019. PMID: 31500112 Free PMC article.
European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance.
Gómez-Gómez E, Carrasco-Valiente J, Blanca-Pedregosa A, Barco-Sánchez B, Fernandez-Rueda JL, Molina-Abril H, Valero-Rosa J, Font-Ugalde P, Requena-Tapia MJ. Gómez-Gómez E, et al. Among authors: requena tapia mj. Urology. 2017 Apr;102:85-91. doi: 10.1016/j.urology.2016.11.004. Epub 2016 Nov 10. Urology. 2017. PMID: 27840252
New Approach to Guide Target Prostate Biopsy: Technique and Initial Experience.
Gómez Gómez E, Valero Rosa J, Carrasco Valiente J, Triviño Tarradas F, Anglada Curado F, López Ruiz D, Requena Tapia MJ. Gómez Gómez E, et al. Among authors: requena tapia mj. Urology. 2018 Nov;121:198-199. doi: 10.1016/j.urology.2017.08.027. Epub 2017 Sep 4. Urology. 2018. PMID: 29074136
[Oligometastatic prostate cancer. concept and implications.].
Carrasco Valiente J, Ruiz García JM, Requena Tapia MJ. Carrasco Valiente J, et al. Among authors: requena tapia mj. Arch Esp Urol. 2018 Mar;71(3):239-246. Arch Esp Urol. 2018. PMID: 29633944 Free article. Review. Spanish.
Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL.
Gomez Gomez E, Salamanca Bustos JJ, Carrasco Valiente J, Fernandez Rueda JL, Blanca A, Valero Rosa J, Bravo Arrebola I, Marquez López J, Jimenez Vacas JM, Luque R, Requena Tapia MJ. Gomez Gomez E, et al. Among authors: requena tapia mj. BMJ Open. 2019 Nov 12;9(11):e031032. doi: 10.1136/bmjopen-2019-031032. BMJ Open. 2019. PMID: 31722940 Free PMC article.
Telomere-based risk models for the early diagnosis of clinically significant prostate cancer.
Rubio Galisteo JM, Fernández L, Gómez Gómez E, de Pedro N, Cano Castiñeira R, Pedregosa AB, Guler I, Carrasco Valiente J, Esteban L, González S, Castelló N, Otero L, García J, Segovia E, Requena Tapia MJ, Najarro P. Rubio Galisteo JM, et al. Among authors: requena tapia mj. Prostate Cancer Prostatic Dis. 2021 Mar;24(1):88-95. doi: 10.1038/s41391-020-0232-4. Epub 2020 May 4. Prostate Cancer Prostatic Dis. 2021. PMID: 32367011 Free PMC article.
Prostate Cancer Patients-Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other Omics.
Fernández-Peralbo MA, Gómez-Gómez E, Calderón-Santiago M, Carrasco-Valiente J, Ruiz-García J, Requena-Tapia MJ, Luque de Castro MD, Priego-Capote F. Fernández-Peralbo MA, et al. Among authors: requena tapia mj. Sci Rep. 2016 Dec 2;6:38243. doi: 10.1038/srep38243. Sci Rep. 2016. PMID: 27910903 Free PMC article. Clinical Trial.
80 results